（此处下载失败可以在在线预览处保存副本或者右键另存为）

【摘要】：肝细胞癌(HCC)是最常见的肝脏恶性肿瘤，对于晚期HCC患者，全身治疗方式有限。瑞戈非尼是一种口服多激酶抑制剂， Ⅲ期临床试验显示其可显著延长晚期HCC患者中位生存期2.8个月，这使得瑞戈非尼成为继索拉非尼后经美国食品药品监督管理局批准用于治疗晚期HCC的二线用药。综述了瑞戈非尼在HCC领域的相关基础和临床研究。
【Abstract】：Hepatocellular carcinoma (HCC) is the most common malignant liver tumor, and there are limited systemic treatments for patients with advanced HCC. Regorafenib is an oral multi-kinase inhibitor, and phase III clinical trial has shown that regorafenib can significantly extend the median survival of patients with advanced HCC by 2.8 months, which makes it a second-line drug approved by FDA for the treatment of advanced HCC, just after sorafenib. This article reviews the basic and clinical research on regorafenib in the field of HCC.
【关键字】：癌，肝细胞；瑞戈非尼；治疗；综述
【Key words】：carcinoma，hepatocellular；regorafenib；therapy；review
【引证本文】：CHEN WB, CAI HH, YANG Y, et al. Research advances in regorafenib in treatment of hepatocellular carcinoma［J］. J Clin Hepatol, 2017, 33(12): 2425-2428. (in Chinese)
陈卫波， 蔡辉华， 杨岳， 等. 瑞戈非尼治疗肝细胞癌的研究进展［J］. 临床肝胆病杂志, 2017, 33(12): 2425-2428.